Who Buys Ceftazidime from India — 360 Importers Behind a $10.7M Market

The importers of Ceftazidime from India can be categorized into several segments:

1. 1Distributors: Entities that purchase large quantities to supply to various healthcare providers.
2. 2Hospital Groups: Healthcare institutions procuring directly for patient care.
3. 3Retail Chains: Pharmacy networks stocking medications for consumer purchase.
4. 4Government Procurement: Organizations like UNICEF or national health ministries acquiring medicines for public health programs.
5. 5Re-exporters: Companies importing with the intent to export to other markets.
6. 6Contract Manufacturers: Firms importing active pharmaceutical ingredients for local production.

Analyzing the top 10 buyers:

1. 1OA&J Pharmaceuticals Ltd. (Ghana, $2.03M): Likely a distributor supplying to various healthcare facilities.
2. 2Ananta Medicare Ukraine Ltd. (Ukraine, $1.20M) and Ananta Medicare Ukraine Limited (Ukraine, $0.36M): Possibly distributors or contract manufacturers, given the significant volumes.
3. 3Biomedic Healthcare Solution (Myanmar, $0.20M): Potentially a distributor or retail chain.
4. 4E P H K (Hungary, $0.17M): Could be a distributor or re-exporter.
5. 5OOO Jodas Expoim (Russia, $0.14M): Likely a distributor.
6. 6V P G (Germany, $0.14M): Possibly a distributor or re-exporter.
7. 7Planetpharma SA (France, $0.13M): Likely a distributor.
8. 8Precious Trust Ltd. (Nigeria, $0.12M): Potentially a distributor.
9. 9To the Receiving Department (South Africa, $0.12M): Could be a hospital group or distributor.

Distributors typically place large, periodic orders to maintain inventory levels, aligning with the repeat buyer rate of 44.7%. Hospital groups and retail chains may order more frequently but in smaller quantities, depending on patient demand. Government procurement entities often engage in tender-based purchasing, leading to bulk orders at specific intervals. Re-exporters and contract manufacturers' purchasing patterns vary based on market demands and production schedules.

Ghana

1. 1Drug Regulatory Authority: Food and Drugs Authority (FDA) Ghana.
2. 2Import Registration Process for Ceftazidime: Importers must register the product with the FDA Ghana, providing comprehensive documentation, including a Certificate of Analysis and Good Manufacturing Practice (GMP) certification.
3. 3Estimated Timeline for Registration: Approximately 3-6 months, depending on the completeness of the application.
4. 4Import Tariff/Duty for HS 30042019: Typically around 5%, but subject to change based on government policies.

Ukraine

1. 1Drug Regulatory Authority: State Service of Ukraine on Medicines and Drugs Control (SMDC).
2. 2Import Registration Process for Ceftazidime: Importers must obtain a license from the SMDC, ensuring compliance with Good Distribution Practice (GDP) and Good Manufacturing Practice (GMP) standards. (cratia.ua)
3. 3Estimated Timeline for Registration: Approximately 6 months, contingent on the application's accuracy and completeness.
4. 4Import Tariff/Duty for HS 30042019: Generally around 10%, but subject to periodic revisions.

Sudan

1. 1Drug Regulatory Authority: National Medicines and Poisons Board (NMPB).
2. 2Import Registration Process for Ceftazidime: Requires product registration with the NMPB, including submission of quality documentation and adherence to local pharmaceutical standards.
3. 3Estimated Timeline for Registration: Approximately 4-8 months, depending on the review process.
4. 4Import Tariff/Duty for HS 30042019: Typically around 5%, but subject to governmental adjustments.

France

1. 1Drug Regulatory Authority: Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM).
2. 2Import Registration Process for Ceftazidime: Requires a Marketing Authorization (MA) from ANSM, involving submission of comprehensive clinical and quality data.
3. 3Estimated Timeline for Registration: Approximately 12-18 months, reflecting the rigorous evaluation process.
4. 4Import Tariff/Duty for HS 30042019: As an EU member, France applies the EU's Common External Tariff, typically around 0-6% for pharmaceuticals.

Myanmar

1. 1Drug Regulatory Authority: Food and Drug Administration (FDA) Myanmar.
2. 2Import Registration Process for Ceftazidime: Importers must register the product with FDA Myanmar, providing necessary documentation, including GMP certification and product samples.
3. 3Estimated Timeline for Registration: Approximately 6-12 months, subject to the review process.
4. 4Import Tariff/Duty for HS 30042019: Typically around 5%, but subject to change based on government policies.

The demand for Ceftazidime, a third-generation cephalosporin antibiotic, is primarily driven by the prevalence of severe bacterial infections, including hospital-acquired pneumonia and sepsis. In countries like Ghana and Nigeria, high incidences of such infections necessitate robust antibiotic procurement. Government healthcare programs aiming to combat antimicrobial resistance and improve infection control further bolster demand.

The inclusion of Ceftazidime in the World Health Organization's Essential Medicines List underscores its critical role in healthcare systems. This designation often leads to its procurement through international tenders and funding from global health initiatives. The expansion of universal health coverage in nations like Myanmar and Sudan enhances access to essential antibiotics, presenting significant market opportunities for suppliers.

The importers of Ceftazidime from India can be categorized into several segments:

1. 1Distributors: Entities that purchase large quantities to supply to various healthcare providers.
2. 2Hospital Groups: Healthcare institutions procuring directly for patient care.
3. 3Retail Chains: Pharmacy networks stocking medications for consumer purchase.
4. 4Government Procurement: Organizations like UNICEF or national health ministries acquiring medicines for public health programs.
5. 5Re-exporters: Companies importing with the intent to export to other markets.
6. 6Contract Manufacturers: Firms importing active pharmaceutical ingredients for local production.

Analyzing the top 10 buyers:

1. 1OA&J Pharmaceuticals Ltd. (Ghana, $2.03M): Likely a distributor supplying to various healthcare facilities.
2. 2Ananta Medicare Ukraine Ltd. (Ukraine, $1.20M) and Ananta Medicare Ukraine Limited (Ukraine, $0.36M): Possibly distributors or contract manufacturers, given the significant volumes.
3. 3Biomedic Healthcare Solution (Myanmar, $0.20M): Potentially a distributor or retail chain.
4. 4E P H K (Hungary, $0.17M): Could be a distributor or re-exporter.
5. 5OOO Jodas Expoim (Russia, $0.14M): Likely a distributor.
6. 6V P G (Germany, $0.14M): Possibly a distributor or re-exporter.
7. 7Planetpharma SA (France, $0.13M): Likely a distributor.
8. 8Precious Trust Ltd. (Nigeria, $0.12M): Potentially a distributor.
9. 9To the Receiving Department (South Africa, $0.12M): Could be a hospital group or distributor.

Distributors typically place large, periodic orders to maintain inventory levels, aligning with the repeat buyer rate of 44.7%. Hospital groups and retail chains may order more frequently but in smaller quantities, depending on patient demand. Government procurement entities often engage in tender-based purchasing, leading to bulk orders at specific intervals. Re-exporters and contract manufacturers' purchasing patterns vary based on market demands and production schedules.

Ghana

1. 1Drug Regulatory Authority: Food and Drugs Authority (FDA) Ghana.
2. 2Import Registration Process for Ceftazidime: Importers must register the product with the FDA Ghana, providing comprehensive documentation, including a Certificate of Analysis and Good Manufacturing Practice (GMP) certification.
3. 3Estimated Timeline for Registration: Approximately 3-6 months, depending on the completeness of the application.
4. 4Import Tariff/Duty for HS 30042019: Typically around 5%, but subject to change based on government policies.

Ukraine

1. 1Drug Regulatory Authority: State Service of Ukraine on Medicines and Drugs Control (SMDC).
2. 2Import Registration Process for Ceftazidime: Importers must obtain a license from the SMDC, ensuring compliance with Good Distribution Practice (GDP) and Good Manufacturing Practice (GMP) standards. (cratia.ua)
3. 3Estimated Timeline for Registration: Approximately 6 months, contingent on the application's accuracy and completeness.
4. 4Import Tariff/Duty for HS 30042019: Generally around 10%, but subject to periodic revisions.

Sudan

1. 1Drug Regulatory Authority: National Medicines and Poisons Board (NMPB).
2. 2Import Registration Process for Ceftazidime: Requires product registration with the NMPB, including submission of quality documentation and adherence to local pharmaceutical standards.
3. 3Estimated Timeline for Registration: Approximately 4-8 months, depending on the review process.
4. 4Import Tariff/Duty for HS 30042019: Typically around 5%, but subject to governmental adjustments.

France

1. 1Drug Regulatory Authority: Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM).
2. 2Import Registration Process for Ceftazidime: Requires a Marketing Authorization (MA) from ANSM, involving submission of comprehensive clinical and quality data.
3. 3Estimated Timeline for Registration: Approximately 12-18 months, reflecting the rigorous evaluation process.
4. 4Import Tariff/Duty for HS 30042019: As an EU member, France applies the EU's Common External Tariff, typically around 0-6% for pharmaceuticals.

Myanmar

1. 1Drug Regulatory Authority: Food and Drug Administration (FDA) Myanmar.
2. 2Import Registration Process for Ceftazidime: Importers must register the product with FDA Myanmar, providing necessary documentation, including GMP certification and product samples.
3. 3Estimated Timeline for Registration: Approximately 6-12 months, subject to the review process.
4. 4Import Tariff/Duty for HS 30042019: Typically around 5%, but subject to change based on government policies.

The demand for Ceftazidime, a third-generation cephalosporin antibiotic, is primarily driven by the prevalence of severe bacterial infections, including hospital-acquired pneumonia and sepsis. In countries like Ghana and Nigeria, high incidences of such infections necessitate robust antibiotic procurement. Government healthcare programs aiming to combat antimicrobial resistance and improve infection control further bolster demand.

The inclusion of Ceftazidime in the World Health Organization's Essential Medicines List underscores its critical role in healthcare systems. This designation often leads to its procurement through international tenders and funding from global health initiatives. The expansion of universal health coverage in nations like Myanmar and Sudan enhances access to essential antibiotics, presenting significant market opportunities for suppliers.